SLC6A3 and attention deficit-hyperactivity disorder: The novel prolintane analogs described here may serve as a valuable starting point for the development of new candidates for ADHD treatment, as they were inactive as releasers at DAT and NET, suggesting a low potential for abuse and cardiovascular stimulation, and they showed lower DAT/SERT ratios.